SCHEMBL13764178

SCHEMBL13764178

CCOC(=O)c1cn2ccnc(NC)c2n1

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.54
ALDH1A1 P00352 3/20 0.54
HPGD P15428 3/20 0.54
POLB P06746 1/20 0.48
HSD17B10 Q99714 2/20 0.41
NPC1 O15118 1/20 0.41
MAPT P10636 1/20 0.41
GAA P10253 1/20 0.40
CYP1A2 P05177 1/20 0.40
CDC7 O00311 1/20 0.39
DBF4 Q9UBU7 1/20 0.39
GABRA2 P47869 4/20 0.39
GABRB2 P47870 4/20 0.39
TMIGD3 P0DMS9 3/20 0.37
ADORA2A P29274 1/20 0.37
ADORA3 P0DMS8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26092626 0.87 KDM4E (0.59) KDM4EALDH1A1HPGDPOLBHSD17B10
SCHEMBL13764181 0.86 KDM4E (0.51) KDM4EALDH1A1HPGDPOLBHSD17B10
SCHEMBL18189912 0.83 KDM4E (0.58) KDM4EALDH1A1HPGDPOLBHSD17B10
SCHEMBL13764176 0.82 KDM4E (0.56) KDM4EALDH1A1HPGDPOLBHSD17B10
SCHEMBL6934846 0.82 KDM4E (0.56) KDM4EALDH1A1HPGDPOLBGAA
SCHEMBL31244472 0.81 KDM4E (0.59) KDM4EALDH1A1HPGDPOLBHSD17B10
SCHEMBL13776906 0.81 TMIGD3 (0.43) TMIGD3ADORA3
SCHEMBL18189892 0.80 KDM4E (0.54) KDM4EALDH1A1HPGDPOLBHSD17B10
SCHEMBL7326240 0.80 KDM4E (0.45) KDM4EALDH1A1HPGDPOLBHSD17B10
SCHEMBL31244541 0.79 KDM4E (0.56) KDM4EALDH1A1HPGDPOLBHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090175852-A1 IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS SCHERING CORPORATION 2009-07-09 US disclosed
US-20090175852-A1 IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS SCHERING CORPORATION 2009-07-09 US disclosed
US-7557104-B2 Imidazopyrazines as protein kinase inhibitors SCHERING CORPORATION (US) 2009-07-07 US disclosed
US-7557104-B2 Imidazopyrazines as protein kinase inhibitors SCHERING CORPORATION (US) 2009-07-07 US disclosed
US-20080027063-A1 IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS SCHERING CORPORATION 2008-01-31 US disclosed
US-20080027063-A1 IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS SCHERING CORPORATION 2008-01-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080027063-A1 IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS CHEK1, CHEK2, CDKN1A KDM4E 857/4885ALDH1A1 3481/4885HPGD 3423/4885
US-20090175852-A1 IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS CHEK1, CHEK2, CDKN1A KDM4E 857/4885ALDH1A1 3481/4885HPGD 3423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.